Thymosin Alpha-1
Synthetic peptide studied in clinical and preclinical models for adaptive immune enhancement and innate immune activation
Last updated: March 1, 2026
- Compound
- Thymosin Alpha-1
- Class
- Immune peptide
- Summary
- Synthetic peptide studied in clinical and preclinical models for adaptive immune enhancement, innate immune activation, balanced immunomodulation.
- Mechanism
- Immune Homeostasis Regulation
- Research Status
- Approved
- Routes Studied
- Subcutaneous injection
- Evidence Level
- Clinically validated · Approved therapeutic
What Should You Know About Thymosin Alpha-1?
- What is Thymosin Alpha-1?
- Thymosin Alpha-1 is a synthetic peptide studied in clinical and preclinical models for adaptive immune enhancement and innate immune activation.
- Is Thymosin Alpha-1 clinically proven?
- Thymosin Alpha-1 is an approved therapeutic with established clinical evidence.
- What has Thymosin Alpha-1 been studied for?
- Thymosin Alpha-1 has been studied in clinical and preclinical settings of adaptive immune enhancement, innate immune activation, balanced immunomodulation and has received regulatory approval in at least one jurisdiction.
- Is Thymosin Alpha-1 approved?
- Thymosin Alpha-1 is an approved therapeutic in at least one jurisdiction. Regulatory status varies by country. Consult a local specialist for guidance.
What Is Thymosin Alpha-1?
Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from Thymosin Fraction 5, a preparation derived from bovine thymus tissue by Allan Goldstein and colleagues at the George Washington University School of Medicine in the 1970s. The peptide's amino acid sequence (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) was subsequently determined and confirmed through chemical synthesis, enabling large-scale production for research and clinical applications. Thymosin Alpha-1 is naturally produced by thymic epithelial cells and circulates...
Evidence Summary
Thymosin Alpha-1 is an approved therapeutic with established clinical evidence and regulatory approval in at least one jurisdiction.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Adaptive Immune Enhancement | Limited |
| Innate Immune Activation | Limited |
| Balanced Immunomodulation | Limited |
| Vaccine Adjuvant Potential | Limited |
| Human clinical evidence | Established |
| Safety data | Established |
Editorial Position
Thymosin Alpha-1 is an approved therapeutic with established clinical evidence. As with any pharmaceutical compound, individual suitability should be discussed with a specialist.
Regulatory Status Snapshot
- Approved as a therapeutic drug in at least one jurisdiction
- Safety and efficacy established through regulatory review processes
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for Thymosin Alpha-1 is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has Thymosin Alpha-1 Been Studied For?
Research areas where Thymosin Alpha-1 has been investigated in published studies
-
Adaptive Immune Enhancement Thymosin Alpha-1 has been studied in clinical and preclinical studies of adaptive immune enhancement.
-
Innate Immune Activation Thymosin Alpha-1 has been studied in clinical and preclinical studies of innate immune activation.
-
Balanced Immunomodulation Thymosin Alpha-1 has been studied in clinical and preclinical studies of balanced immunomodulation.
-
Vaccine Adjuvant Potential Thymosin Alpha-1 has been studied in clinical and preclinical studies of vaccine adjuvant potential.
How Does Thymosin Alpha-1 Work?
These mechanisms have been established through clinical and preclinical research.
- 01 Toll-Like Receptor Engagement
- 02 Intracellular signaling
- 03 Dendritic Cell Maturation
- 04 T-Cell Differentiation & Activation
Not sure if Thymosin Alpha-1 is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about Thymosin Alpha-1.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate Thymosin Alpha-1
How Is Thymosin Alpha-1 Administered?
Thymosin Alpha-1 is available via Subcutaneous injection, auto-injector pen. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of Thymosin Alpha-1?
What Conditions Has Thymosin Alpha-1 Been Linked To?
Have Questions About Thymosin Alpha-1?
Unlike immunostimulants that broadly amplify immune activity, Thymosin Alpha-1 functions as a true immunomodulator. It enhances effector immune responses (T-cell activation, NK cell activity, interferon production) while simultaneously supporting regulatory T-cell function that prevents excessive inflammation.
Over 100 clinical trials across more than 30 countries have studied Thymosin Alpha-1. The synthetic version (thymalfasin/Zadaxin) has received regulatory approval in multiple countries.
Thymosin Alpha-1's immunomodulatory activity means it should be approached with particular caution in individuals with autoimmune disorders. While its regulatory T-cell support may theoretically benefit immune balance, the enhanced Th1 and CTL activity could exacerbate certain autoimmune conditions.
Ready to discuss Thymosin Alpha-1 with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026